Business · 22/02/2007Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for LEVEMIR Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of the biologic medication LEVEMIR, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →